← Leaderboards
Gabriela Chiosis
Sloan-Kettering Inst Can Research
$23,584,161
Attributed
$38,923,234
Total exposure
21
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,923,234 · 21
By mechanism
R01$21,864,961 · 7
RF1$4,816,476 · 1
U01$3,462,991 · 1
R56$2,945,233 · 2
P01$2,842,902 · 2
P50$1,603,533 · 2
Top collaborators
- Stephen D. Ginsberg9 shared
- Mark P. Dunphy8 shared
- Ottavio Arancio5 shared
- Monica L Guzman5 shared
- Jason S Lewis5 shared
- Ari M. Melnick5 shared
- Feixia Chu3 shared
- Nagavarakishore Pillarsetty3 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Elizabeth Victorina Wasmuth$1,145,541
- Jason S Lewis$26,024,327
- Mark P. Dunphy$3,061,237
- Alexander Drilon$4,847,187
- Andrea Ventura$13,315,692
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposProteinsCellsBaseIn VivoMolecular ChaperonesPathway InteractionsDesignComplexAffectMolecularBiologyMalignant NeoplasmsInhibitor/AntagonistResponsePharmaceutical PreparationsIn VitroHeat-Shock Proteins 90Small MoleculeBiologicalBiochemicalLinkLeadNeurons
Grant awards (62)
Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrum$1,151,816
R01 · FY2025 · AG · contact PI
Chaperome networks in Alzheimer's disease$1,125,794
R01 · FY2025 · AG · contact PI
Selective interactome vulnerability across the Alzheimerâs disease spectrum$1,047,941
R01 · FY2025 · AG · contact PI
[18F]-PU-AD epichaperome PET imaging probe$845,131
RF1 · FY2025 · AG · contact PI
[18F]-PU-AD epichaperome PET imaging probe$381,564
RF1 · FY2025 · AG · contact PI
Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrum$1,182,309
R01 · FY2024 · AG · contact PI
Chaperome networks in Alzheimer's disease$1,165,073
R01 · FY2024 · AG · contact PI
Selective interactome vulnerability across the Alzheimerâs disease spectrum$1,076,035
R01 · FY2024 · AG · contact PI
Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrum$1,189,094
R01 · FY2023 · AG · contact PI
Chaperome networks in Alzheimer's disease$1,183,214
R01 · FY2023 · AG · contact PI
Selective interactome vulnerability across the Alzheimerâs disease spectrum$1,165,481
R01 · FY2023 · AG · contact PI
[18F]-PU-AD epichaperome PET imaging probe$3,589,781
RF1 · FY2022 · AG · contact PI
Chaperome networks in Alzheimer's disease$1,199,524
R01 · FY2022 · AG · contact PI
Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrum$1,195,676
R01 · FY2022 · AG · contact PI
Chaperome networks in Alzheimer's disease$1,253,488
R01 · FY2021 · AG · contact PI
Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrum$1,240,570
R01 · FY2021 · AG · contact PI
Selective interactome vulnerability across the Alzheimerâs disease spectrum$1,162,517
R56 · FY2021 · AG · contact PI
Translating Stress Response Targeted Therapy for B-Cell Lymphomas$315,208
P50 · FY2020 · CA · contact PI
A chemical chaperomics platform for AD$877,816
R56 · FY2019 · AG · contact PI
Translating Stress Response Targeted Therapy for B-Cell Lymphomas$308,572
P50 · FY2019 · CA · contact PI
Project 2: Development of grp94-selective Inhibitors for Cancer$260,054
P01 · FY2019 · CA · contact PI
Core 2: Medicinal Chemistry Core$184,386
P01 · FY2019 · CA · contact PI
A chemical chaperomics platform for AD$904,900
R56 · FY2018 · AG · contact PI
Translating Stress Response Targeted Therapy for B-Cell Lymphomas$331,799
P50 · FY2018 · CA · contact PI
Project 2: Development of grp94-selective Inhibitors for Cancer$304,390
P01 · FY2018 · CA · contact PI
Core 2: Medicinal Chemistry Core$292,495
P01 · FY2018 · CA · contact PI
Biomarkers for predicting response to Hsp90 therapy$572,232
R01 · FY2017 · CA · contact PI
Translating Stress Response Targeted Therapy for B-Cell Lymphomas$330,082
P50 · FY2017 · CA · contact PI
Project 2: Development of grp94-selective Inhibitors for Cancer$304,390
P01 · FY2017 · CA · contact PI
Core 2: Medicinal Chemistry Core$292,495
P01 · FY2017 · CA · contact PI
Biomarkers for predicting response to Hsp90 therapy$573,509
R01 · FY2016 · CA · contact PI
Synthesis of Antitumor Natural Products$379,518
R01 · FY2016 · CA · contact PI
Translating Stress Response Targeted Therapy for B-Cell Lymphomas$317,872
P50 · FY2016 · CA · contact PI
Project 2: Development of grp94-selective Inhibitors for Cancer$304,390
P01 · FY2016 · CA · contact PI
Core 2: Medicinal Chemistry Core$302,968
P01 · FY2016 · CA · contact PI
Biomarkers for predicting response to Hsp90 therapy$599,324
R01 · FY2015 · CA · contact PI
Targeting the heat shock response for the therapy of DLBCL$492,767
R01 · FY2015 · CA
Project 2: Development of grp94-selective Inhibitors for Cancer$304,390
P01 · FY2015 · CA · contact PI
Core 2: Medicinal Chemistry Core$292,944
P01 · FY2015 · CA · contact PI
Small molecule Hsp90 inhibitors in AD treatment$663,271
U01 · FY2014 · AG · contact PI
Biomarkers for predicting response to Hsp90 therapy$550,587
R01 · FY2014 · CA · contact PI
Targeting the heat shock response for the therapy of DLBCL$481,623
R01 · FY2014 · CA
Small molecule Hsp90 inhibitors in AD treatment$645,822
U01 · FY2013 · AG · contact PI
Biomarkers for predicting response to Hsp90 therapy$582,268
R01 · FY2013 · CA · contact PI
Targeting the heat shock response for the therapy of DLBCL$474,862
R01 · FY2013 · CA
Biomarkers of response to Hsp90 inhibitors in triple-negative breast cancer$186,970
R21 · FY2013 · CA · contact PI
Small molecule Hsp90 inhibitors in AD treatment$704,140
U01 · FY2012 · AG · contact PI
Targeting the heat shock response for the therapy of DLBCL$514,015
R01 · FY2012 · CA
Biomarkers of response to Hsp90 inhibitors in triple-negative breast cancer$238,685
R21 · FY2012 · CA · contact PI
Small molecule Hsp90 inhibitors in AD treatment$711,474
U01 · FY2011 · AG · contact PI
Targeting the heat shock response for the therapy of DLBCL$541,013
R01 · FY2011 · CA
Design, synthesis and evaluation of selective Grp94 inhibitors$205,994
R21 · FY2011 · AI · contact PI
Small molecule Hsp90 inhibitors in AD treatment$738,284
U01 · FY2010 · AG · contact PI
Design, synthesis and evaluation of selective Grp94 inhibitors$254,420
R21 · FY2010 · AI · contact PI
Assays for rapid identification of Hsp70 modulators$302,962
R01 · FY2008 · CA · contact PI
Hsp90 inhibitors as suppressors of protein misfolding toxicity$182,052
R21 · FY2008 · AG · contact PI
Assays for rapid identification of Hsp70 modulators$302,962
R01 · FY2007 · CA · contact PI
Hsp90 inhibitors as suppressors of protein misfolding toxicity$224,358
R21 · FY2007 · AG · contact PI
Assays for rapid identification of Hsp70 modulators$321,304
R01 · FY2006 · CA · contact PI
Isolation of Inhibitors of Her-Kinase Expression (RMI)$5,154
R03 · FY2005 · MH
FP Assay for Isolation of Hsp90 Inhibitors (RMI)$5,154
R03 · FY2005 · MH
Development of HTS assays probing Hsp90 inhibition (RMI)$84,351
R03 · FY2004 · NS